Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond

British Journal of Cancer, Journal Year: 2020, Volume and Issue: 124(2), P. 345 - 358

Published: Sept. 24, 2020

Abstract Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The majority currently available studies on use this circulating tumour (ctDNA) deal with detection mutations. analysis cfDNA often discussed context noninvasive mutations that lead to resistance mechanisms and therapeutic disease monitoring Indeed, substantial advances have been made area, development methods reach high sensitivity can interrogate a large number genes. Interestingly, however, also be used analyse different features DNA, such as methylation status, size fragment patterns, transcriptomics viral load, which open new avenues for liquid biopsy samples This review will focus perspectives challenges mutation patients solid malignancies.

Language: Английский

---

Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA

Trends in Molecular Medicine, Journal Year: 2021, Volume and Issue: 27(5), P. 482 - 500

Published: Jan. 23, 2021

Language: Английский

---

Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living

Trends in Molecular Medicine, Journal Year: 2020, Volume and Issue: 26(5), P. 519 - 528

Published: Feb. 17, 2020

Language: Английский

---

Cancer nanotechnology: current status and perspectives

Nano Convergence, Journal Year: 2021, Volume and Issue: 8(1)

Published: Nov. 2, 2021

Modern medicine has been waging a war on cancer for nearly century with no tangible end in sight. Cancer treatments have significantly progressed, but the need to increase specificity and decrease systemic toxicities remains. Early diagnosis holds key improving prognostic outlook patient quality of life, diagnostic tools are cusp technological revolution. Nanotechnology steadily expanded into reaches chemotherapy, radiotherapy, diagnostics, imaging, demonstrating capacity augment each advance care. Nanomaterials provide an abundance versatility, functionality, applications engineer specifically targeted medicine, accurate early-detection devices, robust imaging modalities, enhanced radiotherapy adjuvants. This review provides insights current clinical pre-clinical nanotechnological drug therapy, radiation therapy.

Language: Английский

---

HPV post-infection microenvironment and cervical cancer

Cancer Letters, Journal Year: 2020, Volume and Issue: 497, P. 243 - 254

Published: Oct. 27, 2020

Language: Английский

---

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer

Molecular Cancer, Journal Year: 2022, Volume and Issue: 21(1)

Published: March 25, 2022

Abstract Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading cause carcinogenic death. To date, surgical resection regarded as gold standard by operator for clinical decisions. Because conventional tissue biopsy invasive only small sample can sometimes be obtained, it unable to represent heterogeneity tumor or dynamically monitor progression. Therefore, there an urgent need find new minimally noninvasive diagnostic strategy detect CRC at early stage recurrence. Over past years, concept called “liquid biopsy” has gained much attention. Liquid noninvasive, allowing repeated analysis real-time monitoring recurrence, metastasis therapeutic responses. With advanced development molecular techniques in CRC, circulating cells (CTCs), DNA (ctDNA), exosomes, tumor-educated platelet (TEP) detection have achieved interesting inspiring results prominent liquid markers. In this review, we focused on some applications CTCs, ctDNA, exosomes TEPs discuss promising future solve unmet needs patients.

Language: Английский

---

ctDNA monitoring using patient-specific sequencing and integration of variant reads

Science Translational Medicine, Journal Year: 2020, Volume and Issue: 12(548)

Published: June 17, 2020

Integration of variant reads across patient-specific mutation loci enables sensitive ctDNA quantification in plasma cell-free DNA sequencing data.

Language: Английский

---

Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden

Nature Communications, Journal Year: 2021, Volume and Issue: 12(1)

Published: May 28, 2021

Sequencing of cell-free DNA in the blood cancer patients (liquid biopsy) provides attractive opportunities for early diagnosis, assessment treatment response, and minimally invasive disease monitoring. To unlock liquid biopsy analysis pediatric tumors with few genetic aberrations, we introduce an integrated genetic/epigenetic method demonstrate its utility on 241 deep whole-genome sequencing profiles 95 Ewing sarcoma 31 other sarcomas. Our achieves sensitive detection classification circulating tumor peripheral independent any alterations. Moreover, benchmark different metrics fragmentation analysis, LIQUORICE algorithm detecting based cancer-specific chromatin signatures. Finally, combine several fragmentation-based into machine learning classifier that exploits widespread epigenetic deregulation is tailored to cancers low mutation rates. Clinical associations highlight potential value cfDNA patterns as prognostic biomarkers sarcoma. In summary, our study a comprehensive beyond recurrent it renders benefits more readily accessible childhood cancers.

Language: Английский

---

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Jan. 21, 2023

Despite advances in early detection and therapies, cancer is still one of the most common causes death worldwide. Since each tumor unique, there a need to implement personalized care develop robust tools for monitoring treatment response assess drug efficacy prevent disease relapse.

Language: Английский

---

Circulating cell-free DNA for cancer early detection

The Innovation, Journal Year: 2022, Volume and Issue: 3(4), P. 100259 - 100259

Published: May 6, 2022

Effective screening modalities are currently available for only a small subset of cancers, and they generally have suboptimal performance with complicated procedures. Therefore, there is an urgent need to develop simple, accurate, non-invasive methods early detection cancers. Genetic epigenetic alterations in plasma circulating cell-free DNA (cfDNA) shown the potential revolutionize cancers facilitate subsequent diagnosis improve survival patients. The medical interest cfDNA assays has been inspired by emerging single- multi-early studies. This review summarizes current technological clinical advances, hopes providing insights into development applications various scenarios. key phases biomarkers highlighted, future developments cfDNA-based liquid biopsies outlined. It hoped that this study can boost integration workflow.

Language: Английский

---